Phenotypic Screening in Cancer Drug Discovery - Past, Present and Future

Overview

Journal Nat Rev Drug Discov

Specialty Pharmacology

Date 2014 Jul 19

PMID 25033736

Citations 161

Authors

John G Moffat

Joachim Rudolph

David Bailey

Affiliations

Soon will be listed here.

Abstract

There has been a resurgence of interest in the use of phenotypic screens in drug discovery as an alternative to target-focused approaches. Given that oncology is currently the most active therapeutic area, and also one in which target-focused approaches have been particularly prominent in the past two decades, we investigated the contribution of phenotypic assays to oncology drug discovery by analysing the origins of all new small-molecule cancer drugs approved by the US Food and Drug Administration (FDA) over the past 15 years and those currently in clinical development. Although the majority of these drugs originated from target-based discovery, we identified a significant number whose discovery depended on phenotypic screening approaches. We postulate that the contribution of phenotypic screening to cancer drug discovery has been hampered by a reliance on 'classical' nonspecific drug effects such as cytotoxicity and mitotic arrest, exacerbated by a paucity of mechanistically defined cellular models for therapeutically translatable cancer phenotypes. However, technical and biological advances that enable such mechanistically informed phenotypic models have the potential to empower phenotypic drug discovery in oncology.

Citing Articles

The role and application of bioinformatics techniques and tools in drug discovery.

Zhang S, Liu K, Liu Y, Hu X, Gu X Front Pharmacol. 2025; 16:1547131.

PMID: 40017606 PMC: 11865229. DOI: 10.3389/fphar.2025.1547131.

Development of a phenotypic screening assay to measure activation of cancer-associated fibroblasts.

Ilg M, Lapthorn A, Harding S, Minhas T, Koduri G, Bustin S Front Pharmacol. 2025; 16:1526495.

PMID: 40017592 PMC: 11865240. DOI: 10.3389/fphar.2025.1526495.

Advances in the Repurposing and Blood-Brain Barrier Penetrance of Drugs in Pediatric Brain Tumors.

Rechberger J, Toll S, Biswas S, You H, Chow W, Kendall N Cancers (Basel). 2025; 17(3).

PMID: 39941807 PMC: 11816256. DOI: 10.3390/cancers17030439.

Enantioselective Protein Affinity Selection Mass Spectrometry (EAS-MS).

Wang X, Sun J, Ahmad S, Yang D, Li F, Chan U bioRxiv. 2025; .

PMID: 39896675 PMC: 11785093. DOI: 10.1101/2025.01.17.633682.

Metabolic engineering approaches for the biosynthesis of antibiotics.

Yook G, Nam J, Jo Y, Yoon H, Yang D Microb Cell Fact. 2025; 24(1):35.

PMID: 39891166 PMC: 11786382. DOI: 10.1186/s12934-024-02628-2.

References

Prasad A, Park I, Allen H, Zhang X, Reddy M, Boominathan R . Styryl sulfonyl compounds inhibit translation of cyclin D1 in mantle cell lymphoma cells. Oncogene. 2009; 28(12):1518-28. DOI: 10.1038/onc.2008.502. View

Arrowsmith C, Bountra C, Fish P, Lee K, Schapira M . Epigenetic protein families: a new frontier for drug discovery. Nat Rev Drug Discov. 2012; 11(5):384-400. DOI: 10.1038/nrd3674. View

Teicher B, Ara G, Herbst R, Palombella V, Adams J . The proteasome inhibitor PS-341 in cancer therapy. Clin Cancer Res. 1999; 5(9):2638-45. View

Urdiales J, Morata P, Nunez de Castro I, Sanchez-Jimenez F . Antiproliferative effect of dehydrodidemnin B (DDB), a depsipeptide isolated from Mediterranean tunicates. Cancer Lett. 1996; 102(1-2):31-7. DOI: 10.1016/0304-3835(96)04151-1. View

Inai T, Mancuso M, Hashizume H, Baffert F, Haskell A, Baluk P . Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts. Am J Pathol. 2004; 165(1):35-52. PMC: 1618540. DOI: 10.1016/S0002-9440(10)63273-7. View

Stoops S, Pearson A, Weaver C, Waterson A, Days E, Farmer C . Identification and optimization of small molecules that restore E-cadherin expression and reduce invasion in colorectal carcinoma cells. ACS Chem Biol. 2011; 6(5):452-65. PMC: 3401128. DOI: 10.1021/cb100305h. View

Izrailit J, Reedijk M . Developmental pathways in breast cancer and breast tumor-initiating cells: therapeutic implications. Cancer Lett. 2011; 317(2):115-26. DOI: 10.1016/j.canlet.2011.11.028. View

Nakahara T, Kita A, Yamanaka K, Mori M, Amino N, Takeuchi M . YM155, a novel small-molecule survivin suppressant, induces regression of established human hormone-refractory prostate tumor xenografts. Cancer Res. 2007; 67(17):8014-21. DOI: 10.1158/0008-5472.CAN-07-1343. View

Bax D, Little S, Gaspar N, Perryman L, Marshall L, Viana-Pereira M . Molecular and phenotypic characterisation of paediatric glioma cell lines as models for preclinical drug development. PLoS One. 2009; 4(4):e5209. PMC: 2666263. DOI: 10.1371/journal.pone.0005209. View

10.

Snuderl M, Fazlollahi L, Le L, Nitta M, Zhelyazkova B, Davidson C . Mosaic amplification of multiple receptor tyrosine kinase genes in glioblastoma. Cancer Cell. 2011; 20(6):810-7. DOI: 10.1016/j.ccr.2011.11.005. View

11.

Jiang P, Mukthavaram R, Mukthavavam R, Chao Y, Bharati I, Fogal V . Novel anti-glioblastoma agents and therapeutic combinations identified from a collection of FDA approved drugs. J Transl Med. 2014; 12:13. PMC: 3898565. DOI: 10.1186/1479-5876-12-13. View

12.

Mayer T, Kapoor T, Haggarty S, King R, Schreiber S, Mitchison T . Small molecule inhibitor of mitotic spindle bipolarity identified in a phenotype-based screen. Science. 1999; 286(5441):971-4. DOI: 10.1126/science.286.5441.971. View

13.

Chau C, Figg W . New tricks from an old drug: a role for quinacrine in anti-cancer therapy?. Cell Cycle. 2009; 8(24):4024-5. View

14.

HARRISON R . The outgrowth of the nerve fiber as a mode of protoplasmic movement. J Exp Zool. 1959; 142:5-73. DOI: 10.1002/jez.1401420103. View

15.

Kaur G, Stetler-Stevenson M, Sebers S, Worland P, Sedlacek H, Myers C . Growth inhibition with reversible cell cycle arrest of carcinoma cells by flavone L86-8275. J Natl Cancer Inst. 1992; 84(22):1736-40. DOI: 10.1093/jnci/84.22.1736. View

16.

Medina T, Amaria M, Jimeno A . Dabrafenib in the treatment of advanced melanoma. Drugs Today (Barc). 2013; 49(6):377-85. DOI: 10.1358/dot.2013.49.6.1968669. View

17.

Hoelder S, Clarke P, Workman P . Discovery of small molecule cancer drugs: successes, challenges and opportunities. Mol Oncol. 2012; 6(2):155-76. PMC: 3476506. DOI: 10.1016/j.molonc.2012.02.004. View

18.

Lee G, Shim J, Cho B, Jung J, Lee D, Oh I . Stochastic acquisition of a stem cell-like state and drug tolerance in leukemia cells stressed by radiation. Int J Hematol. 2010; 93(1):27-35. DOI: 10.1007/s12185-010-0734-2. View

19.

Begley C, Ellis L . Drug development: Raise standards for preclinical cancer research. Nature. 2012; 483(7391):531-3. DOI: 10.1038/483531a. View

20.

Swinney D . The contribution of mechanistic understanding to phenotypic screening for first-in-class medicines. J Biomol Screen. 2013; 18(10):1186-92. DOI: 10.1177/1087057113501199. View